3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
6
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Burkitt Lymphoma
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Pancreatic Neoplasms
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoblastic Lymphadenopathy
2
Hodgkin Disease
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Advanced Solid Tumors
2
Advanced Nonhematologic Malignancies
2
Advanced Malignancies
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroblastoma
1
Interventions
Cyclophosphamide
41
fludarabine
31
Dexamethasone
27
venetoclax
24
Cytarabine
22
Rituximab
16
pembrolizumab
15
fludarabine phosphate
14
Filgrastim
12
Etoposide
12
Lenalidomide
11
Vincristine
10
Gemcitabine
10
Azacitidine
10
pomalidomide
9
Interleukin-2
9
Granulocyte Colony-Stimulating Factor
9
Doxorubicin
9
Calcium Dobesilate
9
carfilzomib
8
Topotecan
8
Nivolumab
8
Methotrexate
8
Everolimus
8
Decitabine
8
Bortezomib
8
Melphalan
7
Cisplatin
7
Vorinostat
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Recurrence
×
MLN 8237
×
Clear all
NCT02780011
2018-07-27
AD3LE
The Methodist Hospital Research Institute
Phase 1
Withdrawn